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ABSTRACT 
 
Aims 
To determine if urine C‐peptide/creatinine ratio is a useful tool for monitoring β‐cell function in new‐
onset Type 1 diabetes. 
 
Methods 
Data were obtained from a prospective immunomodulation study in people with Type 1 diabetes ≤ 3 
months from diagnosis, with a standard mixed‐meal tolerance test and measurement of urine C‐
peptide/creatinine ratio carried out at 0, 3, 6, 9 and 12 months. The change in the insulin‐dose‐
adjusted HbA1c level was also correlated with the change in serum/urine C‐peptide level during the 
12‐month follow‐up period. 
 
Results 
A significant reduction in urine C‐peptide/creatinine ratio, measured after a mixed‐meal, was 
reached at 9 months (−45.4%), whilst the reduction in stimulated serum C‐peptide level reached 
significance after 3 months (−54.7%) in placebo‐treated participants. Neither change in stimulated 
serum C‐peptide nor change in urine C‐peptide level correlated with each other, and nor did change 
in insulin‐dose‐adjusted HbA1c level in the first 6 months, but all measures correlated significantly in 
the second half of the 12‐month follow‐up period. 
 
Conclusion 
Mixed‐meal‐stimulated urine C‐peptide/creatinine ratio was similar to, although less sensitive than, 
stimulated serum C‐peptide level in monitoring β‐cell function during the first year after diagnosis. 
Because the former is significantly less invasive, it warrants inclusion in further studies in Type 1 
diabetes and may represent an attractive alternative outcome measure in cohort studies and in 
children. 
 
 
 
INTRODUCTION 
With increasing focus on immunomodulation1-4 to preserve β‐cell function in Type 1 diabetes, early 
identification of responders is of particular interest. Impaired β‐cell function results in delayed and 
blunted C‐peptide responses to stimuli5. There is evidence of accelerated β‐cell damage around the 
time of diagnosis6, 7. After resolution of glucotoxicity8 and given that β cells have limited potential for 
proliferation in recent‐onset Type 1 diabetes9, there may be diminished and erratic insulin/C‐peptide 
production early after diagnosis, which may stabilize later. 
 
Most clinical trials use a mixed‐meal tolerance test (MMTT) to assess and monitor β‐cell function10. 
A surrogate measure of β‐cell function, insulin‐dose‐adjusted HbA1c (IDAA1c), correlates well with 
peak serum C‐peptide level 12 months after diagnosis11. Stimulated post‐meal 2‐h urine C‐
peptide/creatinine ratio (urine C‐peptide/creatinine ratio) has also been proposed as less invasive 
alternative means of estimating β‐cell function12. There are limited data and no prospective studies 
comparing urine C‐peptide/creatinine ratio and serum C‐peptide measurements soon after diagnosis 
of Type 1 diabetes. Fasting urine C‐peptide/creatinine ratio has been shown to be insensitive for the 
capture of changing insulin production in an immunointervention trial13; however, its use as a tool for 
monitoring β‐cell function in islet transplant patients suggests that it may have utility14. The less 
invasive nature of urine C‐peptide/creatinine ratio testing makes it potentially attractive as an 
outcome measure in large cohort/community studies. 
 
We compared serial measurements of urine and serum C‐peptide in adults with new‐onset Type 1 
diabetes over 12 months during an intervention trial. 
 
METHODS 
This multicentre, double‐blind randomized controlled intervention trial, was designed to assess the 
safety of C19‐A3 proinsulin peptide and the change in stimulated C‐peptide production between 
baseline and 12 months after treatment in adults with new‐onset Type 1 diabetes. The primary 
outcomes of this study are reported elsewhere (in submission). A total of 27 adults with Type 1 
diabetes of ≤ 3 months’ duration (time from start of insulin to the initiation of study drug ≤ 100 days) 
were recruited between June 2013 and March 2014 from five UK centres. Participants were 
randomized into three groups: placebo (n = 8, age 28.9 ± 8.2 years, women:men ratio = 2:6), low‐
frequency treatment (six 4‐weekly peptide injections; n = 10, age 26.6 ± 5.5 years, women:men ratio 
= 4:6) and high‐frequency treatment (12 peptide injections every 2 weeks; n = 9, age 30.0 ± 5.7 
years, women:men ratio = 3:6). The treatment period was 6 months, followed by a 6‐month 
observation period. Participants received insulin injections as a part of standard clinical care. 
 
The South West 2 Research Ethics Committee (ClinicalTrials.gov identifier NCT01536431, ISRCTN 
66760879) approved the study. All participants gave written informed consent. 
 
Ensure Plus® [Abbott Nutrition, Maidenhead, UK; 6 ml/kg (max 360 ml)] was used as a mixed‐meal 
stimulant of β‐cell production, in both the standard MMTT and the assessment of stimulated urine C‐
peptide/creatinine ratio. The standard MMTT was carried out after overnight fast, as previously 
described10, at 0, 3, 6, 9 and 12 months. Serum samples for C‐peptide and glucose were collected 
at −10, 0, 15, 30, 60, 90 and 120 min. Urine samples were collected from the second void in the 
morning (before MMTT) and 120 min after the MMTT (mixed‐meal‐urine C‐peptide/creatinine ratio) 
with no urine loss in between. 
 
Urine samples were collected in boric acid containers (Sterilin; Thermo Scientific, Newport, UK) and 
transported to a laboratory at ambient temperature within 72 h. If not assayed within 72 h of 
collection they were stored at −80°C for up to 14 days. Serum samples were stored at −20°C and 
transported on dry ice in batches. 
 
Urine C‐peptide level was measured in samples diluted 1:10, using an enzyme‐linked 
immunosorbent assay (Mercodia, Uppsala, Sweden). The detection limit for the C‐peptide assay 
was 25 pmol/l, with intra‐ and inter‐assay coefficients of variation of < 5% and < 5%, respectively. 
Urine creatinine was assayed using a colorimetric method (Jaffe reaction; Randox Ltd, London, UK). 
The detection limit, and intra‐ and inter‐assay coefficients of variation were 100 μmol/l, < 4% and < 
6%, respectively. Results were expressed as urine C‐peptide/creatinine ratio (nmol/mmol). Serum C‐
peptide was measured using an immunochemiluminometric assay (Invitron, Monmouth, UK). The 
detection limit, and intra and inter‐assay coefficients of variation were 5 pmol/l, < 5% and < 8%, 
respectively. 
 
Statistical Analysis 
Data are expressed as mean ± SD or median with interquartile range. Differences were considered 
significant if P value was < 0.05. GRAPHPAD PRISM version 4.0a for Macintosh was used for the 
analysis. 
 
The area under the curve (AUC) was calculated using the trapezoidal method, not adjusted for 
baseline C‐peptide but normalized for the 120‐min period of the standard MMTT using the serum C‐
peptide value at each time point. 
 
The IDAA1c was calculated according to the formula: HbA1c (%) + [4 × insulin dose (units per kg per 
24 h)]11. 
 
Non‐parametric Spearman correlation was performed to correlate the AUC serum C peptide during 
standard MMTT/stimulated urine C‐peptide/creatinine ratio and IDAA1c [change comparing with 
baseline (Δ)]. The strength of association between measures was assessed using correlation 
coefficients (r), slope and P values. The absolute decline in urine C‐peptide/creatinine ratio and AUC 
for C‐peptide was analysed in the placebo group only to exclude treatment effects; correlations with 
IDAA1c were made using change from baseline in all participants. 
 
A Wilcoxon signed‐rank test was used to test the significance of percentage change in relation to the 
baseline value. 
 
RESULTS 
The AUC for serum C‐peptide correlated with peak serum C‐peptide during the MMTT throughout 
the follow‐up period (before: r = 0.98; 3 months: r = 0.98; 6 months: r = 0.83; 9 months: r = 0.94, 12 
months: r = 0.97; all P < 0.0001) and was used as a comparison variable for urine C‐peptide. 
 
A significant reduction in mixed‐meal‐stimulated urine C‐peptide/creatinine ratio was reached at 9 
months (−45.4%, P = 0.03), whilst the reduction in AUC for serum C‐peptide reached significance 
after 3 months (−54.7%, P = 0.008) in placebo‐treated participants, Table 1. 
 
In the pooled analysis of the placebo and treatment groups, the change from baseline in AUC for 
serum C‐peptide did not correlate with the change in the corresponding urine C‐peptide/creatinine 
ratio after 3 months (r = 0.17, P = 0.48). A significant correlation was achieved after 6 months (r = 
0.56, P = 0.007), 9 months (r = 0.65, P = 0.002) and 12 months (r= 0.54, P = 0.02). 
 
Neither change in stimulated serum C‐peptide nor in urine C‐peptide level correlated with change in 
IDAA1c in the first 6 months [mixed‐meal‐stimulated urine C‐peptide/creatinine ratio (Fig. 1a,b); 
mixed‐meal AUC for serum C‐peptide (Fig. 1e,f)]. At 9 and 12 months, both variables correlated 
significantly with IDAA1c [mixed‐meal‐stimulated urine C‐peptide/creatinine ratio, 9 and 12 
months: r = −0.60, P = 0.02; r = −0.68, P = 0.005, respectively (Fig. 1c,d); mixed‐meal AUC for 
serum C‐peptide, 9 and 12 months: r = −0.64, P = 0.002; r = −0.66, P = 0.001, respectively 
(Fig. 1g,h)]. 
 
DISCUSSION 
Although stimulated urine C‐peptide/creatinine ratio correlates with AUC for serum C‐peptide in 
people with established Type 1 diabetes12, there is no information on how urine C‐peptide/creatinine 
ratio performs as a test around the time of diagnosis or in prospective assessment of β‐cell function 
decline. Our data on the placebo‐treated participants with new‐onset Type 1 diabetes only 
(independent of intervention) suggests that stimulated urine C‐peptide/creatinine ratio can be a 
valuable outcome marker to measure decline in β‐cell function over the first 12 (but not 6) months 
from diagnosis (Table 1). Urine C‐peptide/creatinine ratio appears to have slightly less sensitivity to 
change than AUC for serum C‐peptide, potentially requiring a larger sample size, but this needs to 
be balanced against the advantages of convenience and acceptability. 
 
Both urine C‐peptide/creatinine ratio and AUC for serum C‐peptide correlated poorly with a clinical 
measure of β‐cell function, IDAA1c, and with each other in the first 6 months, but improved over the 
second half of the follow‐up period. These findings are consistent with a report of serum analyses 
from the combined TrialNet studies, in which correlation between peak serum C‐peptide level and 
IDAA1c strengthens as the 2‐year follow‐up of > 60 newly diagnosed participants progressed15. 
Buckingham et al.15 observed a correlation with IDAA1c in the first 6 months after diagnosis in 
children, suggesting that the initial lack of correlation in the first 6 months in the present cohort may 
either be specific to adults or attributable to limited power in the present study combined with an 
attenuating effect of the intervention. However, Mortensen et al.11 observed that IDAA1c and serum 
C‐peptide had similar validity in defining partial remission of Type 1 diabetes not earlier than 3 
months from diagnosis. Poor glycaemic control before the diagnosis can certainly influence baseline 
HbA1c and IDAA1c. With participants entering the study within 100 days from diagnosis, this is less 
likely to be the case in this study, with mean starting HbA1c of 57.35 ± 12.60 mmol/l. 
 
It is possible that insulin production is affected by β‐cell stress during the first weeks after diagnosis, 
as measured by proinsulin/C‐peptide ratio16 and β‐cell death17. Furthermore, in participants in the 
placebo arm of early ciclosporin studies, proinsulin/C‐peptide ratio did not normalize until 9 months 
after diagnosis18. It is unlikely that the higher β‐cell reserve observed at the beginning of the study 
had a significant influence, as another study in people after islet‐cell transplant with higher C‐peptide 
production showed a clear correlation between rapidly improving β‐cell function and glycaemic 
control19. 
 
The present study has several limitations. It is possible that the intervention in the treatment group 
may have had a beneficial influence on C‐peptide production. To overcome this, however, the 
correlation between the change in the measurements (IDAA1c and C‐peptide) within the same 
individual was assessed. Differences in gender20 and baseline renal function (C‐peptide excretion) 
should not have an impact on this measure. Changes in renal function during the study might have 
an effect, but were not seen. 
 
Our data provide promising evidence that serial measurements of stimulated urine C‐peptide/ 
creatinine ratio can detect the decline in β‐cell function during the first year after diagnosis, while this 
was not seen using fasting urine C‐peptide in a larger study13. Cross‐sectional studies suggest that 
home post‐meal urine C‐peptide/creatinine ratio samples correlate well with MMTT‐stimulated 
measures12, and may thus be a convenient measure in large‐scale community studies. 
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Table 1. 
Change in mixed meal‐urine C‐peptide/creatinine ratio (n = 7) and mixed meal‐area under the curve 
for serum C‐peptide (n = 8) in placebo‐treated participants in the MonoPepT1De study  
 
P a 
 
0.58 0.11 0.03 0.047 
AUC C peptide ([nmol × min]/l) 
Median 0.53 0.24 0.22 0.30 0.21 
Min 0.30 0.08 0.10 0.08 0.05 
Max 0.98 0.46 0.75 0.89 0.69 
IQR 0.37–0.80 0.19–0.35 0.13–0.44 0.12–0.35 0.15–0.47 
P a 
 
0.008 0.02 0.01 0.02 
 
AUC, area under the curve; IQR, interquartile range. 
a Comparison with time 0. 
P values of < 0.05 are highlighted in bold. 
 
 
 
  
Fig 1 
 
 
Correlation of the change (Δ) in insulin‐dose‐adjusted HbA1c (IDAA1c) and stimulated serum C‐peptide 
and urine C‐peptide responses collected during the follow‐up period. ΔIDAA1c vs Δ mixed‐meal‐urine C‐
peptide/creatinine ratio (UCPCR) (a) after 3 months (r = −0.24, 95% CI −0.63 to 0.23, slope: −1.89 ± 
3.46; P = 0.30, n = 20), (b) after 6 months (r = 0.10, 95% CI −0.38 to 0.54, slope: 0.74 ± 0.76, P = 
0.68, n = 19),(c) after 9 months (r = −0.60, 95% CI −0.85 to −0.13, slope: −2.92 ± 1.52, P = 0.02, n = 16) 
and (d) after 12 months (r = −0.68, 95% CI: −0.88 to −0.26, slope: −1.66 ± 0.60, P = 0.005, n = 16). 
ΔIDAA1c vs Δ mixed meal‐area under the curve for serum C‐peptide collected during the follow‐up period 
(e) after 3 months (r = −0.03, 95% CI −0.43 to 0.39, slope: −0.55 ± 0.63, P = 0.89, n = 24), (f) after 6 
months (r = 0.18, 95% CI −0.24 to 0.54, slope: 0.37 ± 0.42, P = 0.38, n = 25), (g) after 9 months (r = 
−0.64, 95% CI −0.85 to −0.27, slope: −1.92 ± 0.54, P = 0.002, n = 20) and (h) after 12 months (r = −0.66, 
95% CI −0.85 to −0.31, slope: −1.09 ± 0.29, P = 0.001, n = 20). 
